An article analysing how new U.S. tariff policies are contributing to economic...
Fundamentals for Suven Pharmaceuticals Limited
Last Updated:
2025-12-14 19:48
Overall Fundamental outlook
Business Operations:
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
Revenue projections:
Revenue projections for SUVENPHAR With SUVENPHAR's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.
Financial Ratios:
currentRatio
0.000000
forwardPE
56.269436
debtToEquity
1.945000
earningsGrowth
0.755000
revenueGrowth
0.397000
grossMargins
0.627760
operatingMargins
0.316950
trailingEps
10.900000
forwardEps
0.000000
SUVENPHAR's forward PE is elevated, which may cap future price gains and even lead to a price correction. This overvaluation risk highlights the importance of considering this metric carefully in combination with other fundamental indicators to evaluate the stock properly. Positive earnings and revenue growth for SUVENPHAR point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future. SUVENPHAR's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
Price projections:
Price projections for SUVENPHAR SUVENPHAR's current price concerning projections presents no discernible risks or opportunities. This balanced situation suggests a period of stability, where investors might consider holding their positions until more information becomes available.
Recommendation changes over time:
Recommendations trend for SUVENPHAR
Analysts are favoring SUVENPHAR with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider SUVENPHAR as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
An analysis of how sticky inflation and natural disaster risks are creating...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.